PMID- 12631372
OWN - NLM
STAT- MEDLINE
DCOM- 20031217
LR  - 20101118
IS  - 0085-2538 (Print)
IS  - 0085-2538 (Linking)
VI  - 63
IP  - 4
DP  - 2003 Apr
TI  - Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative 
      anticoagulant for hemodialysis, is safe and effective in a dog renal failure 
      model.
PG  - 1548-55
AB  - BACKGROUND: Depolymerized holothurian glycosaminoglycan (DHG) is a new agent with 
      anticoagulant properties quite different from those of unfractionated heparin 
      (UFH) and low-molecular-weight heparin (LMWH) in terms of antithrombin 
      III-dependency, and exerts an antithrombotic effect with less bleeding than UFH 
      and LMWH in vivo. In this study, the anticoagulant and hemorrhagic effects of DHG 
      were investigated on hemodialysis in a dog model of renal failure and compared 
      with those of UFH, LMWH, and nafamostat mesilate (FUT). METHODS: The dog renal 
      failure model was prepared by 7/8 renal artery ligation. Effectiveness was based 
      on completion of 3-hour hemodialysis, no marked clot deposition in the 
      extracorporeal circuit, and permeability of blood urea nitrogen (BUN) and 
      creatinine. Template bleeding was measured by determining the hemoglobin content 
      of the blood from the wound. RESULTS: DHG induced no major bleeding or clot 
      formation during 3-hour hemodialysis, in contrast to UFH and LMWH, each of which 
      induced marked bleeding. These glycosaminoglycans (GAGs) were equally effective 
      in decreasing plasma levels of BUN and creatinine. On the other hand, dogs 
      treated with FUT failed to complete 3-hour hemodialysis. These anticoagulants 
      prolonged activated partial thromboplastin time (APTT) to different extents and 
      GAGs prolonged thrombin clotting time markedly but FUT did not. CONCLUSION: Our 
      findings suggest that thrombin clotting time prolongation can contribute to 
      prevention of clot formation in extracorporeal circuits, and the non-antithrombin 
      III-dependent activities of DHG may be related to its low risk of hemorrhage for 
      hemodialysis. DHG appears to be promising as an alternative anticoagulant with 
      low risk of hemorrhage for hemodialysis.
FAU - Minamiguchi, Kazuhisa
AU  - Minamiguchi K
AD  - Microbial Chemistry Research Foundation, Institute for Chemotherapy, Numazu, 
      Shizuoka, Japan.
FAU - Kitazato, Keiko T
AU  - Kitazato KT
FAU - Nagase, Hideki
AU  - Nagase H
FAU - Sasaki, Eiji
AU  - Sasaki E
FAU - Ohwada, Katsuo
AU  - Ohwada K
FAU - Kitazato, Kenji
AU  - Kitazato K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - 0 (Anticoagulants)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Glycosaminoglycans)
RN  - 0 (depolymerized holothurian glucosaminoglycan)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*pharmacology
MH  - Blood Cell Count
MH  - Blood Coagulation/drug effects
MH  - Disease Models, Animal
MH  - Dogs
MH  - Fatty Acids, Nonesterified/blood
MH  - Glycosaminoglycans/blood/*pharmacology
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Renal Dialysis/*methods
MH  - Renal Insufficiency/*therapy
MH  - Thrombin Time
EDAT- 2003/03/13 04:00
MHDA- 2003/12/18 05:00
CRDT- 2003/03/13 04:00
PHST- 2003/03/13 04:00 [pubmed]
PHST- 2003/12/18 05:00 [medline]
PHST- 2003/03/13 04:00 [entrez]
AID - S0085-2538(15)49034-9 [pii]
AID - 10.1046/j.1523-1755.2003.00879.x [doi]
PST - ppublish
SO  - Kidney Int. 2003 Apr;63(4):1548-55. doi: 10.1046/j.1523-1755.2003.00879.x.